ArticleBiosensors2025
Bridging Blood and Skin: Biomarker Profiling in Dermal Interstitial Fluid (dISF) for Minimally Invasive Diagnostics.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Vitiligo-like depigmentation as an accessible readout of antitumour immunity in melanoma immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Combination of Polymeric Microneedles with Specific Peptide for TNF‑α Sensing Via Noninvasive Detection in Interstitial Fluid.ACS omega · 2026Article
- Recent advances in interstitial fluid dynamics for diagnostic, targeted drug delivery and precision medicine applications.Drug delivery and translational research · 2026Review
- Pilot phase clinical trial of a wearable, electrochemical aptamer-based patch for continuous drug concentration measurement.Nature biotechnology · 2026Article
- The detection of cardiovascular biomarkers in dermal interstitial fluid - a step to real-time monitoring.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Understanding the biochemical relationship between serum and dermal interstitial fluid (dISF) is critical for advancing minimally invasive diagnostics with wearables and point of care devices focusing on most relevant biomarkers accessible in the ISF. This work compares the composition of dISF and serum using Xsensio's microneedle-based collector, which yields an average of 3.4 μL/h. In the first study, total protein content, human serum albumin (HSA), and immunoglobulin G (IgG) are quantified in twelve volunteers. A second study is dedicated to screening 50 inflammation-related protein biomarkers across twenty volunteers. The results demonstrate that dISF closely resembles serum in its major protein constituents but at reduced concentrations (e.g., 57% for total protein). Strong correlations are observed between dISF and serum for CRP and SAA (R2>0.87), primarily driven by a subject with pathological levels, demonstrating the ability of dISF to reflect systemic inflammation. This study originally reports NT-proBNP detection at comparable levels in both fluids, suggesting that dISF could serve as a reliable proxy for blood NT-proBNP in the non-invasive diagnosis of cardiac failure. Cytokine profiling reveals 36 detectable cytokines, including several unique to dISF. Notably, interleukin concentrations are found to be highly similar between the two fluids. These experimental findings support dISF as a promising diagnostic medium for monitoring both localized and systemic biomarkers in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.